Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Ophthalmology · Wet Age-Related Macular Degeneration

Understanding the Biology of Wet AMD

At a Glance

Wet AMD develops when a growth signal called VEGF triggers fragile blood vessels to grow in or beneath the retina and leak fluid or blood into the macula. The leakage distorts central vision, so prompt evaluation and regular retinal scans are important.

While a diagnosis of wet age-related macular degeneration (wet AMD) can feel overwhelming, it is important to know that it is a highly manageable condition with well-established treatments designed to protect and even improve your sight [1][2]. Unlike earlier stages of the disease, wet AMD is an active process where the body attempts to “fix” a lack of oxygen in the eye, inadvertently creating fragile, leaking vessels [3].

By understanding the biological “why” behind these changes, you can work more effectively with your medical team to monitor your progress and maintain your independence.

The Biological Shift: From Dry to Wet

Most people with macular degeneration begin with the “dry” form, which is characterized by the slow breakdown of light-sensitive cells in the macula—the tiny part of your retina responsible for sharp, central vision [1]. Wet AMD (also called neovascular AMD) occurs when this process accelerates due to a specific biological signal [3].

  • VEGF (Vascular Endothelial Growth Factor): This is a protein your body naturally produces to help grow new blood vessels. In the aging eye, factors like oxidative stress and inflammation can cause an overproduction of VEGF [3][4].
  • Macular Neovascularization (MNV): High levels of VEGF signal the growth of abnormal, “neovascular” blood vessels beneath or within the retina [3][5].
  • Fluid and Leakage: Unlike your healthy blood vessels, these new vessels are weak and “leaky.” They spill fluid (serum) or blood into the delicate layers of the macula, causing the retina to swell and distorting your vision [6][3].

This transition can happen relatively quickly, which is why eye doctors emphasize the importance of immediate evaluation if you notice sudden changes in your vision [1][7].

Understanding Your Vision Changes

A common misconception is that wet AMD leads to “total blindness.” In reality, wet AMD is a disease of the central vision [8]. It affects what is directly in front of you—the faces of loved ones, the text in a book, or the numbers on a clock [9].

Symptom What You May Experience
Metamorphopsia Straight lines (like door frames or graph paper) appearing wavy or bent [10].
Central Scotoma A blurry or dark “blind spot” in the very center of your gaze [9].
Micropsia/Macropsia Objects appearing smaller or larger than they actually are [10].
Image Blurring A general loss of sharpness that isn’t corrected by changing your glasses [9].

Because your peripheral (side) vision is relatively preserved, people with wet AMD often maintain basic orientation. However, central vision loss combined with reduced contrast, glare sensitivity, and the possibility of bilateral disease can substantially impair your mobility. This is not a clearance to navigate or drive safely without assessment; you should discuss driving regulations, fall prevention, and low-vision assessment with your care team [8].

Who Is Affected?

Wet AMD is a leading cause of vision loss in older adults [11]. While it can affect anyone, certain factors significantly increase the likelihood of developing the condition:

  • Age: Incidence rises sharply with age [12].
  • Genetics: A significant portion of risk for late-stage AMD is linked to genetic variants in your body’s immune (complement) system. However, genetic risk is not destiny; relatives generally need age-appropriate comprehensive eye exams, not assuming genetic testing is needed [12][13].
  • Lifestyle: Any amount of smoking increases your risk of AMD progression, and risk generally rises with cumulative exposure [12].
  • Ethnicity: Certain subtypes, such as Polypoidal Choroidal Vasculopathy (PCV)—a variant where the vessels form tiny “polyps”—are more common in many East Asian populations, though they occur in all populations and ethnicity does not determine an individual diagnosis [14][15].

What Your Doctor Looks For

To monitor the “wetness” of your AMD, your care team uses advanced imaging called OCT (Optical Coherence Tomography). This scan creates a cross-section of your retina to look for specific types of fluid:

  • Intraretinal Fluid (IRF): Fluid trapped within the layers of the retina itself, which is often associated with more significant vision loss [16][17].
  • Subretinal Fluid (SRF): Fluid that pools underneath the retina. Interestingly, in some cases, small amounts of SRF may be less damaging to vision as fluid within the retina, though this is heavily dependent on the amount, location, and individual response [16][18].
  • Subclinical MNV: Sometimes, a specialized scan called OCT Angiography can detect abnormal vessels before they even begin to leak [5]. If your doctor finds these “nonexudative” vessels, they may recommend much closer monitoring to catch any leakage the moment it starts [19][20].

Note: You should never change or delay treatment based on fluid location or subclinical findings alone; treatment decisions use visual function, scar/atrophy status, and medication regimens.

Early detection is the most powerful tool you have. Research shows that while home tools like the Amsler Grid (a grid of straight lines) are helpful, they are not as sensitive as clinical OCT scans for catching the earliest signs of leakage [21][22]. Regular appointments with a retina specialist are essential for preserving your sight.

Glossary of Key Terms

  • MNV: Macular Neovascularization (abnormal blood vessels).
  • IRF / SRF: Intraretinal Fluid / Subretinal Fluid.
  • PED: Pigment Epithelial Detachment (a blister-like elevation under the retina).
  • OCT / OCTA: Optical Coherence Tomography (imaging scans).
  • PCV: Polypoidal Choroidal Vasculopathy (a subtype of wet AMD).

Common questions in this guide

How does dry AMD become wet AMD?
In wet AMD, aging-related oxidative stress and inflammation can increase VEGF, a signal that promotes blood-vessel growth. Fragile abnormal vessels then form in or beneath the retina and may leak fluid or blood into the macula, distorting central vision.
What symptoms can wet AMD cause?
Wet AMD can make straight lines look wavy, create a blurry or dark spot in the center of vision, or make objects seem unusually small or large. It mainly affects central vision, while side vision is often relatively preserved; a sudden change should prompt an eye evaluation.
What do IRF and SRF mean on my OCT scan?
IRF means fluid within the retinal layers, while SRF means fluid beneath the retina. The importance of either finding depends on its amount and location, your vision, and other retinal changes, so do not change or delay treatment based on the fluid label alone.
What does subclinical MNV mean in the other eye?
Subclinical, or nonexudative, macular neovascularization means abnormal vessels are visible on specialized imaging before they show leakage. Your retina specialist may recommend closer monitoring because leakage can develop later, but the finding alone does not tell you to change treatment.
How is wet AMD monitored at home and in the clinic?
Amsler grid checks can help you notice new waviness, but they are less sensitive than clinical OCT scans for early leakage. Retina specialists use OCT to look for fluid and may use OCT angiography to detect abnormal vessels, so regular appointments remain important.
Can wet AMD cause complete blindness?
Wet AMD primarily damages central vision rather than the entire visual field, so side vision may remain available for orientation. The condition can still seriously affect reading, recognizing faces, mobility, and driving, especially when both eyes are involved; ask your care team about low-vision and safety assessments.
Does smoking increase the risk of wet AMD?
Any amount of smoking increases the risk of AMD progression, and risk generally rises with cumulative exposure. Tell your eye-care team if you currently smoke or smoked in the past so they can discuss your risk and monitoring.

Get notified when new evidence is published on wet macular degeneration.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    Novel approach to antiangiogenic factors in age-related macular degeneration therapy.

    Samelska K, Kupis M, Izdebska J, et al.

    Central-European journal of immunology 2022; (47(1)):117-123 doi:10.5114/ceji.2022.113103.

    PMID: 35600160
  2. 2

    Optical Coherence Tomography-Angiography of Different Choroidal Neovascularization Subtypes in Wet Age-related Macular Degeneration.

    Stavrev VN, Sivkova NP, Koleva-Georgieva DN

    Folia medica 2019; (61(2)):317-326.

    PMID: 31301657
  3. 3

    Macular neovascularization.

    Sheth JU, Stewart MW, Narayanan R, et al.

    Survey of ophthalmology 2025; (70(4)):653-675 doi:10.1016/j.survophthal.2024.08.003.

    PMID: 39222802
  4. 4

    Murine models of neovascular AMD revisited: Mechanistic pathways, immune-metabolic crosstalk, and the impact of aging and sex.

    Harris C, Nisar MA, Amamoo R, et al.

    Experimental eye research 2026; (270()):111094 doi:10.1016/j.exer.2026.111094.

    PMID: 42217724
  5. 5

    Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group.

    Spaide RF, Jaffe GJ, Sarraf D, et al.

    Ophthalmology 2020; (127(5)):616-636 doi:10.1016/j.ophtha.2019.11.004.

    PMID: 31864668
  6. 6

    Influence of lesion location on lesion reactivation after initial treatment in neovascular age-related macular degeneration.

    Kim JH, Kim JW, Kim CG

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2023; (261(11)):3139-3148 doi:10.1007/s00417-023-06144-8.

    PMID: 37314523
  7. 7

    Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration.

    Keane PA, de Salvo G, Sim DA, et al.

    Clinical ophthalmology (Auckland, N.Z.) 2015; (9()):353-66 doi:10.2147/OPTH.S59012.

    PMID: 25733802
  8. 8

    Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy.

    Deng Y, Qiao L, Du M, et al.

    Genes & diseases 2022; (9(1)):62-79 doi:10.1016/j.gendis.2021.02.009.

    PMID: 35005108
  9. 9

    Quality of life in patients with neovascular age-related macular degeneration before and after intravitreal therapy: a longitudinal observational study.

    Nowak M, Cybulska AM, Derezińska A, et al.

    Frontiers in medicine 2026; (13()):1731481 doi:10.3389/fmed.2026.1731481.

    PMID: 42292229
  10. 10

    Relationships of orientation discrimination threshold and visual acuity with macular lesions in age-related macular degeneration.

    Fu H, Zhang B, Tong J, et al.

    PloS one 2017; (12(9)):e0185070 doi:10.1371/journal.pone.0185070.

    PMID: 28922378
  11. 11

    Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial.

    Rakoczy EP, Lai CM, Magno AL, et al.

    Lancet (London, England) 2015; (386(10011)):2395-403.

    PMID: 26431823
  12. 12

    Age-Related Macular Degeneration: A Review.

    Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U

    JAMA 2024; (331(2)):147-157 doi:10.1001/jama.2023.26074.

    PMID: 38193957
  13. 13

    Age-related macular degeneration: Complement in action.

    van Lookeren Campagne M, Strauss EC, Yaspan BL

    Immunobiology 2016; (221(6)):733-9.

    PMID: 26742632
  14. 14

    Anti-Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy.

    Kokame GT, deCarlo TE, Kaneko KN, et al.

    Ophthalmology. Retina 2019; (3(9)):744-752 doi:10.1016/j.oret.2019.04.018.

    PMID: 31511169
  15. 15

    PREVALENCE OF POLYPOIDAL CHOROIDAL VASCULOPATHY IN WHITE PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Systematic Review and Meta-Analysis.

    Lorentzen TD, Subhi Y, Sørensen TL

    Retina (Philadelphia, Pa.) 2018; (38(12)):2363-2371 doi:10.1097/IAE.0000000000001872.

    PMID: 29059101
  16. 16

    Difference Between the Incidence of Retinal Fluid Subtypes and Their Association with Visual Outcomes According to the Types of Macular Neovascularization in a Korean Population.

    Kim JH, Kim JW, Kim CG

    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2022; (38(3)):261-268 doi:10.1089/jop.2021.0103.

    PMID: 35119292
  17. 17

    RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

    Kaiser PK, Wykoff CC, Singh RP, et al.

    Retina (Philadelphia, Pa.) 2021; (41(8)):1579-1586 doi:10.1097/IAE.0000000000003194.

    PMID: 33949342
  18. 18

    Non-exudative fluid in age-related macular degeneration: Imaging, pathophysiology, and clinical implications.

    Vienne-Jumeau A, Merle D, Sacconi R, Querques G

    Survey of ophthalmology 2026; doi:10.1016/j.survophthal.2026.07.008.

    PMID: 42486282
  19. 19

    Nonexudative Macular Neovascularization - A Systematic Review of Prevalence, Natural History, and Recent Insights from OCT Angiography.

    Laiginhas R, Yang J, Rosenfeld PJ, Falcão M

    Ophthalmology. Retina 2020; (4(7)):651-661 doi:10.1016/j.oret.2020.02.016.

    PMID: 32335033
  20. 20

    Two-Year Risk of Exudation in Eyes with Nonexudative Age-Related Macular Degeneration and Subclinical Neovascularization Detected with Swept Source Optical Coherence Tomography Angiography.

    Yang J, Zhang Q, Motulsky EH, et al.

    American journal of ophthalmology 2019; (208()):1-11 doi:10.1016/j.ajo.2019.06.017.

    PMID: 31229464
  21. 21

    Non-invasive testing for early detection of neovascular macular degeneration in unaffected second eyes of older adults: EDNA diagnostic accuracy study.

    Banister K, Cook JA, Scotland G, et al.

    Health technology assessment (Winchester, England) 2022; (26(8)):1-142 doi:10.3310/VLFL1739.

    PMID: 35119357
  22. 22

    Home-monitoring for neovascular age-related macular degeneration in older adults within the UK: the MONARCH diagnostic accuracy study.

    Hogg RE, Wickens R, O'Connor S, et al.

    Health technology assessment (Winchester, England) 2024; (28(32)):1-136 doi:10.3310/CYRA9912.

    PMID: 39023220

This page is for informational purposes only and does not constitute medical advice. It explains wet AMD biology and monitoring; ask your retina specialist how your scans and vision changes should guide your care.

Guide contents wet macular degeneration
Research & Literature
02 Recognizing Symptoms and Understanding Progression